Table 1.
Main characteristics of SSc patients included in the study.
| lcSSc (n=57) | dcSSc (n=39) | All SSc patients (n=96) | P | |
|---|---|---|---|---|
| Age at onset, median ± SD years | 61 (13.68) | 62 (10.88) | 59 (12.87) | ns |
| Gender (Female) (%) | 51 (80.95) | 16 (41.03) | 67 (73.63) | 0.02 |
| Disease duration, mean ± SD years | 7.89 ± 7.34 | 7.5 ± 5.55 | 7.77 ± 6.53 | ns |
| MRSS, mean ± SD | 4 ± 5.11 | 16.93 ± 10.03 | 8.4 ± 8.01 | <0.0001 |
| Active smokers (%) | 17 (26.98) | 8 (20.51) | 25 (27.47) | ns |
| Active disease (%) | 8 (12.7) | 8 (20.51) | 16 (17.58) | 0.0795 |
| Digestive disease (%) | 28 (44.44) | 17 (43.59) | 45 (49.45) | ns |
| Cardiac involvement (%) | 4 (6.35) | 2 (5.13) | 6 (6.59) | ns |
| Raynaud phenomenon (%) | 55 (93.65) | 25 (64.10) | 84 (92.31) | ns |
| Digital ulcers (%) | 6 (9.52) | 8 (20.51) | 14 (15.38) | 0.0286 |
| Synovitis/tenosynovitis (%) | 15 (23.81) | 4 (41.02) | 19 (20.88) | ns |
| Interstitial lung disease (%) | 17 (26.98) | 16 (41.02) | 33 (36.26) | 0.009 |
| TLC, mean ± SD | 1.01 ± 0.15 | 0.95 ± 0.18 | 0.98 ± 0.18 | ns |
| DLCO/VA, mean ± SD | 0.67 ± 0.16 | 0.61 ± 0.19 | 0.65 ± 0.18 | ns |
| FVC, mean ± SD | 1.13 ± 0.21 | 0.88 ± 0.24 | 1.05 ± 0.25 | <0.0001 |
| PAPS, mean ± SD | 32.8 ± 9.05 | 33 ± 10.4 | 32.87 ± 10.92 | ns |
| ANA (%) | 57 (100%) | 39 (100%) | 96 (100%) | ns |
| Anti-scl70 Ab (%) | 5 (7.94) | 19 (48.71) | 20 (21.98) | <0.0001 |
| Anti-centromeres Ab (%) | 39 (61.9) | 2 (5.13) | 41 (45.05) | <0.0001 |
| Anti-ARNpolIII Ab (%) | 1 (1.59) | 3 (7.69) | 4 (4.4) | 0.0849 |
| Methotrexate (%) | 19 (33.33) | 13 (33.33) | 32 (33.33) | ns |
| tDMARDs (%) | 6 (10.53) | 7 (17.95) | 13 (13.54) | ns |
SSc, Systemic Sclerosis; lcSSc, limited cutaneous systemic sclerosis; dcSSc, diffuse cutaneous systemic sclerosis; SD, standard deviation; mRSS, modified Rodnan skin score; TLC, total lung capacity; DLCO, volume-corrected carbon monoxide diffusing capacity; FVC, forced vital capacity; PAPs, systolic pulmonary arterial pressure; ANA, Anti-Nuclear antibody; Ab, antibody; tDMARDs, targeted disease-modifying antirheumatic drugs; ns, not significant.